NEW YORK – Biodesix said Friday that it has entered into a strategic partnership with Datavant to add real-world evidence to its store of lung cancer data and make the anonymized information available to academic and biopharmaceutical researchers.
Boulder, Colorado-based Biodesix plans to anonymize the lung cancer portion of its biobank with the help of Datavant's tokenization process and to connect the information to multiple real-world datasets.
Biodesix said that it has baseline and longitudinal tissue samples on 150,000 cancer patients with genomic and proteomic test results. The firm did not indicate how many of those are from lung cancer.
Biodesix also has data on treatment decisions and outcomes from patients in an ongoing study called INSIGHT.
"With our database and biospecimen repository now linked to the Datavant ecosystem, we can help our partners address a range of clinical, reimbursement, and biomarker questions in lung cancer," Paul Beresford, Biodesix's chief business officer, said in a statement.
"We expect the data to be used for clinically relevant synthetic control arms to help design and execute clinical trials that will ultimately broaden patient access to life-changing drugs," he added.
"We believe connecting the rich Biodesix data to other sources of real-world data will advance the diagnoses, treatment, and research in lung cancer," said Travis May, founder and CEO of San Francisco-based Datavant.